• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc. (Amendment)

    2/14/24 4:19:04 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FULC alert in real time by email
    SC 13G/A 1 d752730dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 3)*

     

     

    Fulcrum Therapeutics, Inc.

    (Name of Issuer)

    COMMON STOCK, $0.001 PAR VALUE PER SHARE

    (Title of Class of Securities)

    359616109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 359616109    SCHEDULE 13G    Page 2 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Third Rock Ventures III, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     PN

     

    (1)

    The percent of class was calculated based on 61,822,554 shares of common stock issued and outstanding as of October 31, 2023 as disclosed in the Issuer’s 10-Q filed with the Securities and Exchange Commission on November 7,2023.


    CUSIP No. 359616109    SCHEDULE 13G    Page 3 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Third Rock Ventures GP III, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP No. 359616109    SCHEDULE 13G    Page 4 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TRV GP III, LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     OO


    CUSIP No. 359616109    SCHEDULE 13G    Page 5 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Third Rock Ventures IV, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     2,343,154

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     2,343,154

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,343,154

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     3.8% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP No. 359616109    SCHEDULE 13G    Page 6 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Third Rock Ventures GP IV, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     2,343,154

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     2,343,154

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,343,154

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     3.8% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP No. 359616109    SCHEDULE 13G    Page 7 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TRV GP IV, LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     2,343,154

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     2,343,154

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,343,154

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     3.8% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     OO


    CUSIP No. 359616109    SCHEDULE 13G    Page 8 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Robert I. Tepper

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     156,189

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     156,189

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     156,189

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0.3% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     IN


    CUSIP No. 359616109    SCHEDULE 13G    Page 9 of 13 Pages

     

    Item 1.

    Issuer

     

      (a)

    Name of Issuer:

    Fulcrum Therapeutics, Inc. (the “Issuer”)

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    26 Landsdowne Street

    Cambridge, MA 02139

     

    Item 2.

    Filing Person

     

      (a) – (c)

    Name of Persons Filing; Address; Citizenship:

     

      (i)

    Third Rock Ventures III, L.P. (“TRV III”);

     

      (ii)

    Third Rock Ventures GP III, L.P. (“TRV GP III”), which is the sole general partner of TRV III;

     

      (iii)

    TRV GP III, LLC (“TRV GP III LLC”), which is the sole general partner of TRV GP III;

     

      (iv)

    Third Rock Ventures IV, L.P. (“TRV IV”);

     

      (v)

    Third Rock Ventures GP IV, L.P. (“TRV GP IV”), which is the sole general partner of TRV IV;

     

      (vi)

    TRV GP IV, LLC (“TRV GP IV LLC”), which is the sole general partner of TRV GP IV; and

     

      (vii)

    Robert I. Tepper (“Tepper,” and collectively with TRV III, TRV GP III, TRV GP III LLC, TRV IV, TRV GP IV and TRV GP IV LLC, the “Reporting Persons”), the managing member of TRV GP III LLC.

    The address of the principal business office of each of the Reporting Persons is Third Rock Ventures, LLC, 201 Brookline Ave, Suite 1401, Boston, MA 02215.

    Each of TRV III, TRV GP III, TRV IV and TRV GP IV is a Delaware limited partnership. Each of TRV GP III LLC and TRV GP IV LLC is a Delaware limited liability company. Tepper is a United States citizen.

     

      (d)

    Title of Class of Securities:

    Common stock, $0.001 par value per share, (the “Common Stock”)

     

      (e)

    CUSIP Number:

    359616109

     

    Item 3.

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under Section 15 of the Act;
    (b)    ☐    Bank as defined in Section 3(a)(6) of the Act;
    (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act;
    (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;


    CUSIP No. 359616109    SCHEDULE 13G    Page 10 of 13 Pages

     

    (e)    ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)    ☐    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
       If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.

    Ownership.

    (a) and (b) Amount beneficially owned:

     

      (i)

    TRV III directly owns 0 shares of Common Stock (the “III Shares”), which represents 0% of the outstanding shares of Common Stock.

     

      (ii)

    TRV GP III is the general partner of TRV III and may be deemed to beneficially own any shares of Common Stock held by TRV III (if any).

     

      (iii)

    TRV GP III LLC is the general partner of TRV GP III and may be deemed to beneficially own any shares of Common Stock held by TRV III (if any).

     

      (iv)

    TRV IV directly owns 2,343,154 shares of Common Stock (the “Shares”), which represents approximately 3.8% of the outstanding shares of Common Stock.

     

      (v)

    TRV GP IV is the general partner of TRV IV and may be deemed to beneficially own the Shares.

     

      (vi)

    TRV GP IV LLC is the general partner of TRV GP IV and may be deemed to beneficially own the Shares.

     

      (vii)

    As the managing member of TRV GP III LLC Tepper may be deemed to beneficially own any shares of Common Stock held by TRV III (if any). Additionally, Tepper directly owns 156,189 shares of Common Stock, which represents approximately 0.3% of the outstanding shares of Common Stock.

     

      (c)

    Number of shares as to which such person has:

     

         Number of Shares of Common Stock  
    Reporting Person    (i)      (ii)      (iii)      (iv)  

    TRV III

         0        0        0        0  

    TRV GP III

         0        0        0        0  

    TRV GP III LLC

         0        0        0        0  

    TRV IV

         0        2,343,154        0        2,343,154  

    TRV GP IV

         0        2,343,154        0        2,343,154  

    TRV GP IV LLC

         0        2,343,154        0        2,343,154  

    Tepper

         156,189        0        156,189        0  


    CUSIP No. 359616109    SCHEDULE 13G    Page 11 of 13 Pages

     

      (i)

    Sole power to vote or direct the vote

     

      (ii)

    Shared power to vote or to direct the vote

     

      (iii)

    Sole power to dispose or to direct the disposition of

     

      (iv)

    Shared power to dispose or to direct the disposition of

    The percent of class was calculated based on 61,822,554 shares of common stock issued and outstanding as of October 31, 2023 as disclosed in the Issuer’s 10-Q filed with the Securities and Exchange Commission on November 7, 2023.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    Not applicable.


    CUSIP No. 359616109    SCHEDULE 13G    Page 12 of 13 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2024

     

    THIRD ROCK VENTURES III, L.P.
    By: THIRD ROCK VENTURES GP III, L.P.,
    General Partner
    By: TRV GP III, LLC,
    General Partner
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer
    THIRD ROCK VENTURES GP III, L.P.
    By: TRV GP III, LLC,
    General Partner
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer
    TRV GP III, LLC
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer
    THIRD ROCK VENTURES IV, L.P.
    By: THIRD ROCK VENTURES GP IV, L.P.,
    General Partner
    By: TRV GP IV, LLC,
    General Partner
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer


    CUSIP No. 359616109    SCHEDULE 13G    Page 13 of 13 Pages

     

    THIRD ROCK VENTURES GP IV, L.P.
    By: TRV GP IV, LLC,
    General Partner
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer
    TRV GP IV, LLC
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer
    ROBERT I. TEPPER

    /s/ Kevin Gillis, As attorney-in-fact

    Robert I. Tepper
    Get the next $FULC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FULC

    DatePrice TargetRatingAnalyst
    9/13/2024$17.00 → $4.00Buy → Neutral
    H.C. Wainwright
    9/12/2024$15.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    9/12/2024$4.00Outperform → Market Perform
    Leerink Partners
    9/12/2024$10.00 → $2.00Neutral → Underperform
    BofA Securities
    9/12/2024Buy → Hold
    Stifel
    9/12/2024Overweight → Neutral
    Cantor Fitzgerald
    9/9/2024$5.00 → $10.00Underperform → Neutral
    BofA Securities
    5/20/2024$23.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $FULC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employees an aggregate of 260,

      5/9/25 4:30:00 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fulcrum Therapeutics to Participate in Upcoming May Conferences

      CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences: H.C. Wainwright BioConnect Investor Conference at NASDAQMay 20, 2025New York, New York RBC Capital Markets Global Healthcare ConferenceMay 21, 2025Fireside Chat at 3:35 pm ET, Participation link: HERENew York, New York The webcast of the fireside chat will be accessible by visiting the "Events and Presentations" section of Fulcrum Therapeutics' websi

      5/8/25 4:05:00 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

      ― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended Q1 2025 with $226.6 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improv

      5/1/25 7:00:00 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FULC
    Leadership Updates

    Live Leadership Updates

    See more
    • Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

      CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality assurance officer. Together, Ms. Kalofonos and Ms. Faulds will be instrumental in advancing losmapimod towards a New Drug Application (NDA) submission and preparing for commercial launch. "I am excited to welcome Isabel to our leadership team as we continue to advance towards the potential approval a

      8/19/24 7:00:00 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

      ―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum's executive leadership team as senior vice president (SVP) of early development ― CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Patrick Horn, M.D., Ph.D., as

      3/18/24 7:00:00 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fulcrum Therapeutics Appoints Chief Financial Officer

      CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Alan A. Musso as chief financial officer, effective August 7, 2023. A 30-year veteran in the life sciences industry, Mr. Musso has held numerous financial and operational leadership positions over the course of his career. "We are delighted to welcome Alan to our executive leadership team," said Alex C. Sapir, president and chief executive officer at Fulcrum Therapeutics. "Alan's wealth of industry experience and impressive track record

      8/3/23 6:55:00 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FULC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $FULC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Fulcrum Therapeutics downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Fulcrum Therapeutics from Buy to Neutral and set a new price target of $4.00 from $17.00 previously

      9/13/24 7:32:27 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fulcrum Therapeutics downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Fulcrum Therapeutics from Outperform to Sector Perform and set a new price target of $4.00 from $15.00 previously

      9/12/24 3:56:30 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fulcrum Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Fulcrum Therapeutics from Outperform to Market Perform and set a new price target of $4.00

      9/12/24 12:22:27 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

      SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

      11/14/24 4:25:46 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

      SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

      11/14/24 6:15:07 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

      SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

      11/12/24 3:51:00 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FULC
    SEC Filings

    See more
    • SEC Form DEFR14A filed by Fulcrum Therapeutics Inc.

      DEFR14A - Fulcrum Therapeutics, Inc. (0001680581) (Filer)

      5/7/25 4:37:59 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc.

      SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

      5/2/25 5:33:17 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Fulcrum Therapeutics Inc.

      10-Q - Fulcrum Therapeutics, Inc. (0001680581) (Filer)

      5/1/25 7:10:20 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FULC
    Financials

    Live finance-specific insights

    See more
    • Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

      ― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended Q1 2025 with $226.6 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improv

      5/1/25 7:00:00 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

      CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2025 financial results will be released on Thursday, May 1, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and u

      4/24/25 8:00:00 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

      ― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended 2024 with $241.0 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for the fourth quart

      2/25/25 7:00:00 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FULC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sapir Alex bought $492,028 worth of shares (43,360 units at $11.35) (SEC Form 4)

      4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

      3/5/24 4:15:17 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FULC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Principal Accounting Officer Tourangeau Greg sold $2,520 worth of shares (498 units at $5.06), decreasing direct ownership by 3% to 14,062 units (SEC Form 4)

      4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

      5/9/25 4:15:04 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Musso Alan A

      4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

      1/28/25 4:15:14 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Oltmans Curtis Gale

      4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

      1/28/25 4:15:06 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care